On November 9, Terray Therapeutics (hereinafter referred to as "Terray"), a biotechnology company headquartered in Pasadena, California, announced that it has receivedNVIDIA's venture capital arm NVenturesEquity investment, but the specific amount has not been disclosed.
This round of financing was led byNVIDIALed by [omitted], with John Maraganore, founding CEO of Alnylam Pharmaceuticals, and Bassil Dahiyat, founder and CEO of Xencor, participating.It is reported that this is NVIDIA's investment since 2023The 9thAI pharmaceutical company.In this wave of AI explosion, NVIDIA has not only reaped gains in the secondary marketTrillion USD Market Value, and has become one of the most important roles in the primary market through investment.Since its establishment in 2018,Terray Therapeutics has been committed to accelerating the speed and success rate of small molecule drug discovery and development through large-scale experiments and generative AI.Previously, Terray Therapeutics, Inc.Completed on February 15, 2022$60 Million Series A Financing, with investors including Alexandria Venture Investments, Digitalis Ventures, Goldcrest Capital, Greentrail Capital, KdT Ventures, Madrona, Sahsen Ventures, Two Sigma Ventures, and XTX Ventures.After receiving investment from NVIDIA this time, Terray will utilizeNVIDIA DGX™ CloudDevelop the world's most comprehensive foundational models for small-molecule chemistry, some of which will be available on the NVIDIA BioNeMo™ cloud service for generative AI in drug discovery.
ThroughNVIDIA AI Software Stack and NVIDIA's Full-Stack Computing Expertise, will help Terray optimize and expand the development of its foundational models.These advances will pave the way for Terray Therapeutics to leverage its proprietary experimental datasets to create powerful ligand-based and structure-based models, further advancing Terray's pipeline into the clinic.Terray Therapeutics explores molecules and targets through the sophisticated integration of ultra-high-throughput experiments, generative AI, biology, medicinal chemistry, automation, and nanotechnology.Its platform is specifically built for generative AI-driven drug discovery, integrating chemical experiments and computations at an unprecedented scale.Jacob Berlin, Ph.D., CEO of Terray TherapeuticsSaid: "The scale, precision, and quality of the experimental data enable us to harness the power of NVIDIA technology to train our foundational chemical models. These models allow our generative AI to effectively explore vast molecular spaces to address complex challenges in drug discovery."Mohamed "Sid" Siddeek, Head of NVenturesSaid: "Generative AI is having a huge impact on the biotechnology industry, and the new approach to training AI foundation models on NVIDIA's accelerated computing platform will help Terray Therapeutics achieve breakthrough innovations in drug discovery."References:
https://www.terraytx.com/press/terray-therapeutics-announces-investment-from-nvidia-to-enable-generative-ai-design-for-drug-discovery
